Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FTRE
HoldHot AirFortrea Holdings Inc. · Healthcare · United States · $1.8B · Avg Vol: $23M/d
COMPANY DESCRIPTION
Fortrea Holdings Inc. is a global contract research organization (CRO) providing clinical development, patient access, and post-approval services to pharmaceutical and biotechnology companies. Its extensive global footprint, deep scientific and therapeutic expertise, and integrated suite of services position it as a critical partner in accelerating drug development for biopharma clients. Fortrea is a significant independent CRO in the drug development ecosystem.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.8B | 2.8B | 2.7B | 2.7B | -1.4% | 2.7B | 2.7B | 2.7B | 0.4% |
| EPS | 2.11 | -0.04 | -3.67 | -10.81 | — | -0.83 | — | — | — |
| Shares | 88.8M | 88.8M | 89.7M | 93.1M | +4.8% | 95.1M | — | — | — |
| Debt | 63.4M | 1.7B | 1.2B | 1.1B | 160.1% | 1.1B | — | — | — |
| Equity | 3.3B | 1.7B | 1.4B | 563.5M | -44.8% | — | — | — | — |
| Op CF | 82.7M | 168.4M | 262.8M | 113.5M | 11.1% | 227.8M | — | — | — |
| Inv CF | -54.0M | -31.8M | 251.6M | 14.4M | — | — | — | — | — |
| Fin CF | -6.3M | -140.8M | -497.8M | -76.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FTRE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FTRE | Fortrea Holdings Inc.(you) | $1.8B | 60 | Hold |
| VCEL | Vericel Corporation | $2.1B | 56 | Hold |
| SEPN | Septerna, Inc. | $1.8B | 52 | Hold |
| ADMA | ADMA Biologics, Inc. | $2.1B | 53 | Hold |
| URGN | UroGen Pharma Ltd. | $2.1B | 51 | Hold |
| MGTX | MeiraGTx Holdings plc | $1.3B | 68 | Buy |
| OMER | Omeros Corporation | $1.3B | 48 | Hold |
| SRPT | Sarepta Therapeutics, Inc. | $2.2B | 46 | Hold |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.0B | 50 | Hold |
| SLS | SELLAS Life Sciences Group, Inc. | $2.7B | 44 | Hold |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%